Ayrshire Capital Management LLC Buys 765 Shares of Eli Lilly and Company $LLY

Key Points

• Ayrshire Capital Management LLC increased its stake in Eli Lilly and Company by 9.8% in the second quarter, holding 8,592 shares valued at approximately $6.7 million.
• Eli Lilly reported earnings per share (EPS) of $6.31 for the last quarter, exceeding estimates and marking a 37.6% year-over-year revenue increase.
• The company recently declared a quarterly dividend of $1.50, representing an annual yield of 0.8% with a payout ratio of 39.22%.

Ayrshire Capital Management LLC boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 9.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,592 shares of the company's stock after buying an additional 765 shares during the period. Eli Lilly and Company makes up approximately 3.2% of Ayrshire Capital Management LLC's investment portfolio, making the stock its 16th largest holding. Ayrshire Capital Management LLC's holdings in Eli Lilly and Company were worth $6,698,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. WestEnd Advisors LLC boosted its position in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the 1st quarter worth approximately $27,000. Citizens National Bank Trust Department boosted its position in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company in the 1st quarter worth approximately $40,000. Finally, Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $43,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded down $9.41 during trading hours on Friday, hitting $753.52. The stock had a trading volume of 7,319,147 shares, compared to its average volume of 3,181,974. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a market capitalization of $713.17 billion, a price-to-earnings ratio of 49.25, a PEG ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.86. The stock's fifty day moving average is $738.37 and its two-hundred day moving average is $770.79.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on LLY shares. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and raised their target price for the stock from $675.00 to $700.00 in a research note on Wednesday, August 27th. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus target price of $939.61.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jamere Jackson purchased 200 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.